SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Mudcat who wrote (28982)6/26/1999 8:09:00 PM
From: Henry Niman  Respond to of 32384
 
Since you don't seem to understand the difference between oral and topical Targretin, it might be useful to discuss the difference and why LGND chose to file for oral first. Topical is the gel referenced in your Bear Stearns report (which of course lends NO support for a 4Q filing of oral Targretin), while oral is a pill, like the one that advance breast cancer patients and patients with severe or moderate psoriasis are taking).


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News